GlaxoSmithKline Gets Formal EU Okay for Breast Cancer Drug

LONDON, June 12 (Reuters) - GlaxoSmithKline Plc has received formal European marketing authorization for its new breast cancer pill Tyverb, the world’s second biggest drugmaker said on Thursday.

MORE ON THIS TOPIC